Key result
S-ICDs prevent lead complications in young cardiac arrest survivors but lack antitachycardia and bradycardia pacing.
Why the study?
Selecting an ICD for young survivors of out-of-hospital cardiac arrest requires balancing the pacing capabilities of TV-ICDs against the lead-related complications avoided by S-ICDs.
Does the subcutaneous implantable cardioverter defibrillator (S-ICD) improve safety and outcomes compared to the transvenous implantable cardioverter defibrillator (TV-ICD) in young cardiac arrest survivors?
Does the subcutaneous implantable cardioverter defibrillator (S-ICD) improve safety and outcomes compared to the transvenous implantable cardioverter defibrillator (TV-ICD) in young cardiac arrest survivors?
S-ICDs are an important alternative to TV-ICDs for young cardiac arrest survivors who do not require pacing, as they avoid the high cumulative risk of transvenous lead-related complications.
Answers are grounded in this paper and cite their sources.
May support S-ICD use in young arrest survivors without pacing needs; leaves open randomized comparative outcome data.
Secondary prevention implantable cardioverter defibrillators (ICDs) are indicated in young patients presenting with aborted sudden cardiac death (SCD) because of ventricular arrhythmias. Transvenous-ICDs (TV-ICDs) are effective, established therapies supported by evidence. The significant morbidity associated with transvenous leads led to the development of the newer subcutaneous-ICD (S-ICD). This review discusses the clinical considerations when selecting an ICD for the young patient presenting with out-of-hospital cardiac arrest. The major benefits of TV-ICDs are their ability to pace (antitachycardia pacing [ATP], bradycardia support and cardiac resynchronisation therapy [CRT]) and the robust evidence base supporting their use. Other benefits include a longer battery life. Significant complications associated with transvenous leads include pneumothorax and tamponade during insertion and infection and lead failure in the long term. Comparatively, S-ICDs, by virtue of having no intravascular leads, prevent these complications. S-ICDs have been associated with a higher incidence of inappropriate shocks. Patients with an indication for bradycardia pacing, CRT or ATP (documented ventricular tachycardia) are seen as unsuitable for a S-ICD. If venous access is unsuitable or undesirable, S-ICDs should be considered given the patient is appropriately screened. There is a need for further randomised controlled trials to directly compare the two devices. TV-ICDs are an effective therapy for preventing SCD limited by significant lead-related complications. S-ICDs are an important development hindered largely by an inability to pace. Young patients stand to gain the most from a S-ICD as the cumulative risk of lead-related complications is high. A clinical framework to aid decision-making is presented.
No takes yet. Share an insight, caveat, or question.
Morton et al. (2023) conducted a review in Aborted sudden cardiac death. Subcutaneous implantable cardioverter defibrillators (S-ICD) vs. Transvenous implantable cardioverter defibrillators (TV-ICD) was evaluated. Subcutaneous ICDs prevent transvenous lead-related complications in young cardiac arrest survivors but are hindered by an inability to provide antitachycardia or bradycardia pacing.
Synapse has enriched 10 related papers. Consider them for comparative context: